Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma

R. J. Motzer, N. M. Tannir, D. F. McDermott, O. Arén Frontera, B. Melichar, T. K. Choueiri, E. R. Plimack, P. Barthélémy, C. Porta, S. George, T. Powles, F. Donskov, V. Neiman, C. K. Kollmannsberger, P. Salman, H. Gurney, R. Hawkins, A. Ravaud, M. O. Grimm, S. BracardaC. H. Barrios, Y. Tomita, D. Castellano, B. I. Rini, A. C. Chen, S. Mekan, M. B. McHenry, M. Wind-Rotolo, J. Doan, P. Sharma, H. J. Hammers, B. Escudier

Hematology & Oncology
Internal Medicine

Research output: Contribution to journal › Article › peer-review

3109 Scopus citations

Sort by
Weight
Alphabetically

Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma

Fingerprint

Medicine & Life Sciences